Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227

被引：0

作者：

Reck, Martin ^{[1
]}

Brahmer, Julie R. ^{[2
]}

Lee, Jong-Seok ^{[3
]}

Ciuleanu, Tudor-Eliade ^{[4
,5
]}

Caro, Reyes Bernabe ^{[6
]}

Nishio, Makoto ^{[7
]}

Urban, Laszlo ^{[8
]}

Audigier-Valette, Clarisse ^{[9
]}

Lupinacci, Lorena ^{[10
]}

Sangha, Randeep ^{[11
]}

Paz-Ares, Luis ^{[12
]}

Borghaei, Hossein ^{[13
]}

O'byrne, Kenneth John ^{[14
,15
]}

Gupta, Ravi G. ^{[16
]}

Bushong, Judith ^{[16
]}

Li, Li ^{[16
]}

Blum, Steven I. ^{[16
]}

Eccles, Laura ^{[16
]}

Ramalingam, Suresh S. ^{[17
]}

机构：

[1] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany

[2] Johns Hopkins Kimmel Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA

[3] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea

[4] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania

[5] Univ Med & Pharm Iulia Hatieganu, Cluj Napoca, Romania

[6] Hosp Univ Virgen Rocio, Inst Biomed Seville, Seville, Spain

[7] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[8] Matrai Gyogyintezet, Matrahaza, Hungary

[9] Hop St Musse, Orientat Oncolog Pole14, Toulon, France

[10] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina

[11] Cross Canc Inst, Edmonton, AB, Canada

[12] Univ Complutense Madrid, Hosp Univ 12 Octubre, Madrid, Spain

[13] Fox Chase Canc Ctr, Philadelphia, PA USA

[14] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia

[15] Queensland Univ Technol, Brisbane, Qld, Australia

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Emory Univ, Winship Canc Inst, Atlanta, GA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

920

引用

页码：162 / 162

页数：1

共 50 条

[31] Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M.
Ciuleanu, T. -E.
Dols, M. C.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Vidal, O. J.
Alexandru, A.
Sakai, H.
Scherpereel, A.
Lu, S.
John, T.
Carbone, D. P.
Meadows-Shropshire, S.
Yan, J.
Paz-Ares, L. G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S2
[32] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, Martin
Ciuleanu, Tudor-Eliade
Dols, Manuel Cobo
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurella
Sakai, Hiroshi
Scherpereel, Arnaud
Lu, Shun
John, Thomas
Carbone, David Paul
Meadows-Shropshire, Stephanie
Yan, Jinchun
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
[34] Six-year survival and HRQoL outcomes with 1L nivolumab (N) plus ipilimumab (I) vs chemotherapy (C) in patients with metastatic NSCLC (mNSCLC) from CheckMate227
Ramalingam, Suresh S.
Ciuleanu, Tudor-Eliade
Bernabe Caro, Reyes
Nishio, Makoto
Mizutani, Hideaki
Lee, Jong-Seok
Audigier-Valette, Clarisse
Sangha, Randeep
Urban, Laszlo
Burgers, Jacobus A.
Pluzanski, Adam
Lee, Ki Hyeong
Zurawski, Bogdan
Schenker, Michael
Peters, Solange
Paz-Ares, Luis
Borghaei, Hossein
O'byrne, Kenneth
Brahmer, Julie R.
Gupta, Ravi G.
Bushong, Judith
Li, Li
Yuan, Yong
Blum, Steven
Reck, Martin
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 129 - 130
[35] First-line (1L) nivolumab (N) plus ipilimumab (I) with two cycles of chemotherapy (chemo) in patients with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the non-interventional FINN study
Kuon, Jonas
von der Heyde, Eyck
Bischoff, Marina
Wilop, Stefan
Behringer, Dirk
Blau, Wolfgang
Huebner, Gerdt
Flieger, Dimitri
Forstbauer, Helmut
Groschek, Matthias
Laack, Heinz-Eckart
Mueller-Huesmann, Harald
Schumann, Christian
Waldenberger, Daniela
Guetz, Sylvia
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 132 - 132
[36] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
Hellmann, M. D.
Rizvi, N.
Gettinger, S. N.
Goldman, J.
Chow, L. Q.
Juergens, R.
Borghaei, H.
Brahmer, J.
Shen, Y.
Harbison, C. T.
Nathan, F.
Ready, N. E.
Antonia, S. J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
[37] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
Greil, R.
Kato, K.
Ajani, J.
Doki, Y.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C. -H
Adenis, A.
El Hajbi, F.
Di Bartolomeo, M.
Braghiroli, M. Ignez
Holtved, E.
Murphy, M. Blum
Patel, A.
Hu, N.
Matsumura, Y.
Chau, I
Kitagawa, Y.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
[38] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
Chau, Ian
Ajani, Jaffer A.
Kitagawa, Yuko
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Murphy, Mariela A. Blum
Nathani, Raheel
Hu, Nan
Matsumura, Yasuhiro
Kato, Ken
Doki, Yuichiro
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[40] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Chau, Ian
Ajani, Jaffer A.
Doki, Yuichiro
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez Freitas Melro
Holtved, Eva
Murphy, Mariela A. Blum
Abdullaev, Sandzhar
Soleymani, Samira
Lei, Ming
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →